RxDoctor Payments Data

Michael Ryder, DO

Family Medicine · Medford, NYNPI 1659598589

Payments from drug & device makers

$5,417in general payments, 2019–2025

Across 301 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$617
  • Novo Nordisk$510
  • Otsuka America Pharmaceutical, Inc.$467
  • Boehringer Ingelheim$445
  • Lilly USA, LLC$393
  • Pfizer$357
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,411100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,417 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$443,266
Medicare patients
957
Services billed
4,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$181,770
OzempicSemaglutide115$119,187
JardianceEmpagliflozin63$65,539
TrulicityDulaglutide40$56,548
NuplazidPimavanserin Tartrate22$56,401
Nurtec OdtRimegepant Sulfate26$49,690
FarxigaDapagliflozin Propanediol73$49,435
MounjaroTirzepatide37$45,846
EntrestoSacubitril/Valsartan89$44,859
XareltoRivaroxaban77$39,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$37,318
LinzessLinaclotide58$36,967
SantylCollagenase Clostridium Hist.65$35,717
JanuviaSitagliptin Phosphate56$31,262
ProcritEpoetin Alfa23$17,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Abrysvo$357$239,094412 claims
Novo NordiskOzempic$510$119,187115 claims
Lilly USA, LLCTrulicity, Mounjaro$393$102,39577 claims
Boehringer IngelheimJardiance, Tradjenta$445$69,40378 claims
Johnson & JohnsonXarelto, Procrit$137$57,358100 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$159$50,737102 claims
AstraZenecaFarxiga$339$49,43573 claims
NovartisEntresto$199$44,85989 claims
AbbVieLinzess, Lumigan$617$41,06570 claims
MerckJanuvia$154$31,26256 claims
Astellas Pharma US IncMyrbetriq$35$15,61940 claims
Avanir Pharmaceuticals, Inc.Nuedexta$67$8,76611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Medford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →